Bibliography
- WENZEL SE, WESTCOTTJY, SMITH HR, LARSEN GL: Spectrum of prostanoid release after bronchoalveolar allergen challenge in atopic asthmatics and in control groups. An alteration in the ratio of bronchoconstrictive to bronchoprotective mediators. Am. Rev Respir. Di s (1989) 139(2):450–457.
- MCKENNIFF MG, RODGER IW, NORMAN P, GARDINER PJ: Characterisation of receptors mediating the contractile effects of prostanoids in guinea-pig and human airways. Eur: Pharmacol (1988) 153(2-3):149–159.
- MCKENNIFF MG, NORMAN P, CUTHBERT NJ, GARDINER PJ: BAY u3405, a potent and selective thromboxane A2 receptor antagonist on airway smooth muscle M vitro. Br. Pharmacol (1991) 104(3):585–590.
- GERVAIS FG, CRUZ RP, CHATEAUNEUF A et al.: Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP.' Allergy Chit. Immunol. (2001) 108(6):982–988.
- MENCIU C, DUFLOS M, FOUCHARD F et al.: New N-(pyridin-4-y1)-(indo1-3-yl)acetamides and propanamides as antiallergic agents. J. Med. Chem. (1999) 42(4):638–648.
- SUGIMOTO H, SHICHIJO M, IINO T et al.: An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro. Pharmacol Exp. Ther. 305(1):347–352
- •Clear indication that ramatroban acts on CRTH2 receptors as well as TP receptors.
- SAWYER N, CAUCHON E, CHATEAUNEUF A et al: Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br. J. Pharmacol (2002) 8:1163–1172.
- •Most detailed characterisation of the ligand specificity of the CRTH2 receptor.
- FORD-HUTCHINSON AW, GIRARD Y, LORD A et al.: The pharmacology of L-670596, a potent and selective thromboxane/prostaglandin endoperoxide receptor antagonist. Can. J. Physic] Phannacol (1989) 67(9):989–993.
- NO AUTHORS LISTED: The use of DP receptor antagonists to treat allergic rhinitis. Expert Opin. Ther. Patents (2002) 12:597–599.